

W Robert Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4092949/publications.pdf>

Version: 2024-02-01

64
papers

488
citations

687335

13
h-index

713444

21
g-index

66
all docs

66
docs citations

66
times ranked

654
citing authors

#	ARTICLE	IF	CITATIONS
1	Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy. <i>Cancer</i> , 2007, 109, 1506-1512.	4.1	56
2	Practice patterns for peer review in radiation oncology. <i>Practical Radiation Oncology</i> , 2015, 5, 32-38.	2.1	53
3	External beam irradiation of prostate cancer. Conformal treatment techniques and outcomes for the 1990. <i>Cancer</i> , 1995, 75, 1972-1977.	4.1	37
4	Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828. <i>Practical Radiation Oncology</i> , 2014, 4, 187-191.	2.1	30
5	Prostate Cancer and the Hypofractionation Hypothesis. <i>Journal of Clinical Oncology</i> , 2013, 31, 3849-3851.	1.6	28
6	The High Number of Unfilled Positions in the 2019 Radiation Oncology Residency Match: Temporary Variation or Indicator of Important Change?. <i>Practical Radiation Oncology</i> , 2019, 9, 300-302.	2.1	28
7	A Call for Change in the ABR Initial Certification Examination in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 17-20.	0.8	22
8	Unfilled Positions in the 2020 Radiation Oncology Residency Match: No Longer an Isolated Event. <i>Practical Radiation Oncology</i> , 2020, 10, e307-e308.	2.1	22
9	Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. <i>Brachytherapy</i> , 2009, 8, 191-196.	0.5	20
10	Extreme hypofractionation for prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 61-65.	2.4	16
11	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men. <i>JAMA Network Open</i> , 2021, 4, e2139769.	5.9	16
12	Computer-Based Learning in Medical Education: A Critical View. <i>Journal of the American College of Radiology</i> , 2006, 3, 793-798.	1.8	15
13	NRG Oncology RTOG 0415: A randomized phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 1-1.	1.6	14
14	Six Questions to Ask Before We Shorten Radiation Treatments for Intact Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 718-721.	0.8	13
15	Thoughts on the American Board of Radiology Examinations and the resident experience in radiation oncology. <i>Practical Radiation Oncology</i> , 2018, 8, 298-301.	2.1	11
16	Hypofractionation for prostate cancer: tested and proven. <i>Lancet Oncology</i> , The, 2016, 17, 1020-1022.	10.7	10
17	Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1271-1278.	0.8	10
18	Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer. <i>Journal of Palliative Medicine</i> , 2015, 18, 933-939.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Cost-Effectiveness of Primary Radiation Therapy Versus Radical Prostatectomy for Intermediate- to High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 383-390.	0.8	7
20	Reconciling outcomes for Black men with prostate cancer within and outside the Veterans Health Administration. <i>Cancer</i> , 2021, 127, 342-344.	4.1	7
21	Radiation therapy following radical prostatectomy. <i>Cancer</i> , 1995, 75, 1909-1913.	4.1	6
22	Moderate hypofractionation for prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 321-329.	1.4	5
23	Unfilled Positions in the 2021 Radiation Oncology Match. <i>Practical Radiation Oncology</i> , 2021, 11, 323-324.	2.1	5
24	T2-T3 carcinoma of the supraglottic larynx:A comparison of surgery and radiotherapy. <i>Radiation Oncology Investigations</i> , 1994, 2, 237-244.	0.9	4
25	Prostate brachytherapy: A descriptive analysis from CaPSURE. <i>Brachytherapy</i> , 2007, 6, 123-128.	0.5	4
26	We Need Better Figures!. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 236.	0.8	4
27	Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415. <i>PLoS ONE</i> , 2021, 16, e0249123.	2.5	4
28	Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction. <i>Future Oncology</i> , 2007, 3, 649-654.	2.4	3
29	Invited commentary on GETUG-AFU 16. <i>Translational Andrology and Urology</i> , 2016, 5, 958-960.	1.4	3
30	Radiation Biology for Radiation Oncology Residents: An Alternative View. <i>Practical Radiation Oncology</i> , 2019, 9, 504-505.	2.1	3
31	Phase II trial of 6 months ADT/abiraterone acetate plus prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11-11.	1.6	3
32	Effect of the Adoption of a Comprehensive Electronic Health Record on Graduate Medical Education: Perceptions of Faculty and Trainees. <i>Southern Medical Journal</i> , 2018, 111, 476-483.	0.7	3
33	In regard to Wu and Vapiwala et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 858-859.	0.8	2
34	Protonâ€beam therapy after radical prostatectomy: Continued DVH idolatry?. <i>Cancer</i> , 2019, 125, 4136-4138.	4.1	2
35	Comments on: High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localize prostate cancer: toxicity and 6-years biochemical results. <i>Brachytherapy</i> , 2019, 18, 426.	0.5	2
36	Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiotherapy In Patients with Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2021, 7, 100805.	1.2	2

#	ARTICLE	IF	CITATIONS
37	Phase II trial enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in men with high-risk PSA recurrent prostate cancer (PC): The STREAM trial.. Journal of Clinical Oncology, 2019, 37, 29-29.	1.6	2
38	Facilitating the Transition to Independent Radiation Oncology Practice Through a Resident-Led, Veterans Affairs Teaching Hospital Service. Practical Radiation Oncology, 2021, 11, 441-447.	2.1	2
39	We need better randomized comparison trials of prostate cancer. Cancer, 2010, 116, 270-272.	4.1	1
40	Reporting of Uncertainty at the 2013 Annual Meeting of the American Society for Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2014, 89, 222-223.	0.8	1
41	Six-Year Checkup: Narrowing the Scope of Practical Radiation Oncology. Practical Radiation Oncology, 2016, 6, 1-2.	2.1	1
42	Scholarly Publishing and the Metric System. International Journal of Radiation Oncology Biology Physics, 2018, 101, 784-785.	0.8	1
43	Gratitude Is the Attitude: Acknowledgments After 10 Years With Practical Radiation Oncology. Practical Radiation Oncology, 2021, 11, 1-2.	2.1	1
44	Radiation Therapy for Clinically Localized Prostate Cancer. , 2008, , 505-517.		1
45	Pretreatment serum prostate-specific antigen (PSA) level and PSA doubling times (PSADT) in black and white men with prostate cancer referred for radiation therapy. Radiation Oncology Investigations, 1996, 4, 135-139.	0.9	0
46	Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?. Nature Clinical Practice Oncology, 2006, 3, 534-535.	4.3	0
47	In Reply to Dr. Lawrence. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1276-1277.	0.8	0
48	The development of oncology treatment guidelines: an analysis of the National Guidelines Clearinghouse. Practical Radiation Oncology, 2011, 1, 33-37.	2.1	0
49	Seduced by technology?. Cancer, 2015, 121, 2300-2302.	4.1	0
50	Why the Aversion?. Journal of Graduate Medical Education, 2017, 9, 255-255.	1.3	0
51	In recognition of the 2017 PRO reviewer apprentices. Practical Radiation Oncology, 2018, 8, 297.	2.1	0
52	Grateful Recognition of PRO Reviewer Apprentices and Reviewers of the Year. Practical Radiation Oncology, 2020, 10, 141.	2.1	0
53	Editor's Note. Practical Radiation Oncology, 2020, 10, 73.	2.1	0
54	What Can Journals Do to Increase the Reliability of Scientific Research?. Practical Radiation Oncology, 2020, 10, 139-140.	2.1	0

#	ARTICLE	IF	CITATIONS
55	Lycopene Dietary Supplements and Prostate Cancer Treatment. <i>Seminars in Preventive and Alternative Medicine</i> , 2006, 2, 72-75.	0.1	0
56	Intensity-Modulated Radiotherapy. , 2013, , 749-759.		0
57	External Beam Radiation Therapy for Clinically Localized Prostate Cancer. , 2015, , 731-742.		0
58	A nomogram for testosterone recovery following combined androgen deprivation therapy and radiation therapy for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 67-67.	1.6	0
59	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9-9.	1.6	0
60	Prostate cancer specific mortality and overall survival outcomes for salvage radiation therapy after radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017, 2017, 9-9.	1.6	0
61	Optimal timing of post-prostatectomy radiotherapy for prostate cancer with high-risk pathologic features: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 24-24.	1.6	0
62	Multi-institutional analysis of synchronous prostate and rectosigmoid cancers.. <i>Journal of Clinical Oncology</i> , 2019, 37, 33-33.	1.6	0
63	Early salvage versus adjuvant therapy for treatment of prostate cancer following prostatectomy. <i>BMJ Evidence-Based Medicine</i> , 2021, 26, bmjebm-2020-111592.	3.5	0
64	Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	2.1	0